The Diabetes Prevention Program is a nationwide clinical study to answer the question: Can Type 2 diabetes (also called noninsulin-dependent or adult-onset diabetes) be prevented or delayed? The study has recruited volunteers, who are at high risk of developing diabetes, at twenty-five medical centers in the United States. It is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and other Institute and corporate sponsors. Researchers will evaluate the efficacy of a lifestyle intervention and a pharmacological intervention in preventing or delaying Type 2 diabetes in persons with impaired glucose tolerance (IGT). Each person in the study will be followed for 3 to 6 years.

Inclusion Criteria:

• Impaired glucose tolerance (fasting plasma glucose 95-125 mg/dL and 2hr plasma glucose 140-199 mg/dL)
• BMI >= 24 kg/m2

Exclusion Criteria:

• Underlying disease likely to limit life span and/or increase risk of interventions
• Conditions or behaviors likely to effect conduct of the DPP
• Diabetes or disordered glucose metabolism
• Suboptimally treated Thyroid disease
• Fasting triglyceride level < 600 mg/dl
• Exclusions related to medications